Journal issues
Contents
Free online sample copy
E-mail alert
Register
Search

Editorial
Editor
Instructions to authors
Scope
Audience
Related journals
Citation
Indexed in
Supplement enquiry

Customer services
Subscribe
Sample copy
Reprint request
Permissions

Stockton
Contacts
News
Help

Journal home

Journal of Human Hypertension

Journal of Human Hypertension publishes latest research on new drug…

Volume 13, issue 10 (Oct 1999) contains a very important research paper from a team of scientists led by J M Mallion from the Michallon Hospital in France.
This work represents another step forward in the effective treatment of hypertensive patients.

The title of this paper is…………
ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension.
JM Mallion, JP Siche and Y Lacourcière

Abstract:
The antihypertensive efficacy and tolerability profiles of the selective AT₁ receptor antagonists telmisartan and losartan were compared with placebo in a 6-week, multinational multicentre, randomised, double-blinded, double dummy, parallel-group study of 223 patients with mild to moderate hypertension, defined as clinic diastolic blood pressure (DBP) =95 and =114mm Hg, clinic systolic pressure (SBP) =140 and =200 mm Hg, and 24-h ambulatory DBP =85mm Hg. After a 4-week single-blind placebo run-in, eligible patients were randomised to receive telmisartan 40mg, telmisartan 80 mg, losartan 50 mg, or placebo. Ambulatory blood pressure monitoring (ABPM) after 6 weeks of double-blind therapy showed that all active treatments produced significant (P< 0.01) reductions from baseline in 24-h mean SBP and DBP compared with placebo.

During the 18-12 h period after dosing, the reductions in SBP/DBP with telmisartan 40 mg (10.7/6.8 mm Hg) and 80 mg (12.2/7.1 mm Hg) were each significantly (P< 0.05) greater than those observed for losartan 50 mg (6.0/3.7 mm Hg), and losartan was no better than placebo. Also for the 24-h mean blood pressure, telmisartan 40 mg and 80 mg were significantly (P< 0.05) better than Losartan 50 mg. Compared with losartan, telmisartan 80 mg produced significantly (P< 0.05) greater reductions in both SBP and DBP during all monitored periods of the 24-h period, while telmisartan 40 mg produced significantly greater reductions in SBP and DBP in the night-time period (10.01 pm to 5.59 am) (P< 0.05) and in DBP in the morning period (6.00 am to 11.59 am) (P< 0.05).

All treatments were comparably well tolerated. Telmisartan 40 mg and 80 mg once daily were effective and well tolerated in the treatment of mild-to-moderate hypertension, producing sustained 24-h blood pressure control which compared favourably to losartan.

About this article:
This article will be published in the October 1999 issue of the Journal of Human Hypertension (Volume 13, Number 10), pages 657 – 664

This paper is only one example of the innovative work that is published in every issue of the Journal of Human Hypertension. If you would like to purchase a copy of this article then please contact Theresa Emerick on t.emerick@nature.com or alternatively fax us on +44 (0) 1256 810526.

For more information on the Journal of Human Hypertension please browse through the journal home pages.